At a glance

Type

Peptide / related clinical research

Regulatory context

The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.

Evidence

Clinical reports suggest questions worth studying, but incomplete design reporting, small samples and surrogate endpoints limit confidence and generalisation.

What it is

Semax is a synthetic peptide related to a fragment of adrenocorticotropic hormone. Its neurological research should be read in the context of the particular illness, preparation and outcome studied. It is not interchangeable with ACTH itself or with other peptides marketed for focus. [1]

Early stroke research

A 1997 clinical report compared 30 people receiving Semax during acute ischaemic stroke care with 80 controls receiving conventional therapy. The authors reported neurological and electrophysiological changes. The abstract does not provide enough information about allocation and masking to treat this as definitive evidence of a reliable treatment effect. [1]

Rehabilitation research

A 2018 report examined 110 people after ischaemic stroke, divided by rehabilitation timing and Semax exposure. It measured plasma BDNF, motor performance and Barthel functional scores, reporting associations with improved recovery. The abstract does not clearly establish random allocation or blinding. Rehabilitation timing and other care complicate causal interpretation. [2]

Brain imaging is not a clinical benefit

A 2020 study of 52 healthy participants compared Semax, Selank and placebo using resting-state functional MRI. Measurements at five and twenty minutes assessed connectivity changes. Such short-term imaging observations do not demonstrate better memory, work performance or recovery from disease. [3]

What remains uncertain

The studies involve different clinical questions and cannot be pooled informally into a general “brain optimisation” claim. Independent replication, patient-relevant outcomes and longer safety follow-up would be needed to judge broader use. A mechanistic marker such as BDNF is not a substitute for a meaningful clinical outcome. [1] [2] [3]

Questions for your doctor

Which diagnosis and endpoint does the evidence actually address? What established care would be used instead or alongside it? Symptoms suggestive of a stroke require emergency assessment, not experimentation with a peptide. This guide is not a dosing or self-treatment protocol. [1] [2]

Safety and clinical context

FDA notes limited safety information and potential immunogenicity concerns for Semax. These studies do not establish long-term safety or unsupervised use. [4]

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.